Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know

The development of vaccines to fight COVID-19 has been a remarkable medical achievement. However, this global immunization effort has been complicated by a rare vaccine-related outcome characterized by thrombocytopenia and thrombosis in association with platelet-activating anti–platelet factor 4 ant...

Descripción completa

Detalles Bibliográficos
Autores principales: Arepally, Gowthami M., Ortel, Thomas L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2021
Materias:
Blood Spotlight
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8172307/
https://www.ncbi.nlm.nih.gov/pubmed/34323940
http://dx.doi.org/10.1182/blood.2021012152
_version_ 1783702516768178176
author Arepally, Gowthami M.
Ortel, Thomas L.
author_facet Arepally, Gowthami M.
Ortel, Thomas L.
author_sort Arepally, Gowthami M.
collection PubMed
description The development of vaccines to fight COVID-19 has been a remarkable medical achievement. However, this global immunization effort has been complicated by a rare vaccine-related outcome characterized by thrombocytopenia and thrombosis in association with platelet-activating anti–platelet factor 4 antibodies. In this Spotlight, we will discuss the recently described complication of vaccine-induced immune thrombotic thrombocytopenia (VITT) occurring in response to certain COVID-19 vaccines. Although information about this clinical condition is rapidly evolving, we will summarize our current understanding of VITT.
format Online
Article
Text
id pubmed-8172307
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American Society of Hematology
record_format MEDLINE/PubMed
spelling pubmed-81723072021-06-03 Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know Arepally, Gowthami M. Ortel, Thomas L. Blood Blood Spotlight The development of vaccines to fight COVID-19 has been a remarkable medical achievement. However, this global immunization effort has been complicated by a rare vaccine-related outcome characterized by thrombocytopenia and thrombosis in association with platelet-activating anti–platelet factor 4 antibodies. In this Spotlight, we will discuss the recently described complication of vaccine-induced immune thrombotic thrombocytopenia (VITT) occurring in response to certain COVID-19 vaccines. Although information about this clinical condition is rapidly evolving, we will summarize our current understanding of VITT. American Society of Hematology 2021-07-29 /pmc/articles/PMC8172307/ /pubmed/34323940 http://dx.doi.org/10.1182/blood.2021012152 Text en © 2021 by The American Society of Hematology
spellingShingle Blood Spotlight
Arepally, Gowthami M.
Ortel, Thomas L.
Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know
title Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know
title_full Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know
title_fullStr Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know
title_full_unstemmed Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know
title_short Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know
title_sort vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know
topic Blood Spotlight
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8172307/
https://www.ncbi.nlm.nih.gov/pubmed/34323940
http://dx.doi.org/10.1182/blood.2021012152
work_keys_str_mv AT arepallygowthamim vaccineinducedimmunethromboticthrombocytopeniawhatweknowanddonotknow
AT ortelthomasl vaccineinducedimmunethromboticthrombocytopeniawhatweknowanddonotknow

Ejemplares similares